

**Ref:** EPL/CS/SE/0056/2025**Date:** July 09, 2025

To,

<b>National Stock Exchange of India Limited</b> Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051  <b>Script Symbol: EMCURE</b>	<b>BSE Limited</b> P J Towers, Dalal Street, Mumbai - 400 001  <b>Scrip Code/Symbol: 544210/ EMCURE</b>
--	--

Dear Sir/Madam,

**Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") - US FDA inspection at our manufacturing facility (Oncology) located at Sanand, Ahmedabad, Gujarat, India.**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the United States Food and Drug Administration ("US FDA") had conducted Pre-Approval Inspection ("PAI") of Company's manufacturing facility (Oncology) located at G.I.D.C., Taluka - Sanand, Ahmedabad - 382110, Gujarat, from June 30, 2025 to July 08, 2025. The inspection concluded without issuance of Form 483 (zero observations).

You are requested to take the above information on your records.

Thanking you,

**For Emcure Pharmaceuticals Limited**

**Chetan Sharma**  
**Company Secretary & Compliance Officer**  
**Membership Number: F8352**

**Emcure Pharmaceuticals Limited****Registered Office:** Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India**Phone Nos.:** +91 20 - 35070033/ 35070000 **Fax No.:** +91 20 3507 0060**E-mail:** corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251